← Back to Search

Gain-framed messages for Cervical Cancer

N/A
Waitlist Available
Led By Xiaoli Nan
Research Sponsored by University of Maryland, College Park
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years or older
Self-identify as African American
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline posttest (test was approximately 5 minutes to complete)
Awards & highlights

Study Summary

A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination

Eligible Conditions
  • Cervical Cancer
  • Anal Cancer
  • Penile Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline posttest (test was approximately 5 minutes to complete)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline posttest (test was approximately 5 minutes to complete) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Attitudes
Intention to Vaccinate Free of Cost
Secondary outcome measures
Intention to Vaccinate With Cost

Side effects data

From 2012 Phase 3 trial • 6104 Patients • NCT01346592
27%
Injection site pain
25%
Pyrexia
14%
Upper respiratory tract infection
14%
Decreased appetite
14%
Diarrhea
10%
Injection site erythema
9%
Nasopharyngitis
9%
Irritability postvaccinal
9%
Headache
8%
Vomiting
8%
Injection site induration
7%
Hypersomnia
7%
Myalgia
7%
Injection site swelling
7%
Fatigue
6%
Crying
6%
Injection site hemorrhage
4%
Gastroenteritis
1%
Pneumonia
1%
Animal Bite
100%
80%
60%
40%
20%
0%
Study treatment Arm
ATIV (6 to <72 Months)
TIV (6 to <72 Months)
Comparator TIV (6 to <72 Months)

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Loss-framed messagesExperimental Treatment1 Intervention
Participants in this arm receive loss-framed HPV vaccination messages.
Group II: Gain-framed messagesExperimental Treatment1 Intervention
Participants in this arm receive gain-framed HPV vaccination messages.
Group III: Control messagesActive Control1 Intervention
Participants in this arm receive non-framed HPV vaccination messages.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HPV vaccination messages
2021
N/A
~1170

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,926,171 Total Patients Enrolled
University of Maryland, College ParkLead Sponsor
154 Previous Clinical Trials
44,315 Total Patients Enrolled
Xiaoli NanPrincipal InvestigatorUniversity of Maryland, College Park
1 Previous Clinical Trials
456 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~281 spots leftby Mar 2025